Price
Financials
Standalone, Rs crore| Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 48 | 57 | 67 | 80 |
| Expenses | 39 | 45 | 52 | 65 |
| Operating Profit | 9 | 11 | 15 | 15 |
| OPM % | 19% | 20% | 22% | 19% |
| Other Income | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 2 | 2 | 2 |
| Profit before tax | 8 | 10 | 13 | 14 |
| Tax % | 27% | 24% | 23% | 25% |
| Net Profit | 6 | 8 | 10 | 11 |
| EPS in Rs | 3.10 | 4.21 | 4.32 | 4.56 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 0 | 59 | 76 | 100 | 105 | 147 |
| Expenses | 0 | 53 | 65 | 83 | 84 | 117 |
| Operating Profit | 0 | 6 | 11 | 17 | 21 | 30 |
| OPM % | 11% | 14% | 17% | 20% | 20% | |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 2 | 3 | 4 |
| Profit before tax | 0 | 6 | 10 | 15 | 18 | 27 |
| Tax % | 26% | 26% | 25% | 25% | 25% | |
| Net Profit | 0 | 4 | 7 | 11 | 13 | 21 |
| EPS in Rs | 0.00 | 1,800.00 | 2,880.00 | 4,452.00 | 7.37 | 8.87 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | 25% | 40% | ||
| Compounded Profit Growth | % | % | 42% | 54% | ||
| Stock Price CAGR | % | % | % | 47% | ||
| Return on Equity | % | 45% | 39% | 30% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 0.03 | 0.03 | 18 | 23 |
| Reserves | 0 | 4 | 12 | 23 | 18 | 78 |
| Borrowings | 0 | 1 | 1 | 0 | 0 | 0 |
| Other Liabilities | -0 | 12 | 16 | 18 | 34 | 23 |
| Total Liabilities | 0 | 18 | 28 | 41 | 70 | 124 |
| Fixed Assets | 0 | 3 | 6 | 14 | 19 | 28 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 2 |
| Other Assets | 0 | 15 | 22 | 27 | 52 | 90 |
| Total Assets | 0 | 18 | 28 | 41 | 70 | 124 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | 4 | 7 | 9 | 7 | 4 |
| Cash from Investing Activity | 0 | -3 | -5 | -8 | -9 | -25 |
| Cash from Financing Activity | 0 | 1 | 0 | -1 | -0 | 45 |
| Net Cash Flow | 0 | 1 | 2 | 0 | -2 | 23 |
| Free Cash Flow | 0 | 1 | 2 | 1 | -1 | -21 |
| CFO/OP | 89% | 87% | 70% | 56% | 41% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 64 | 66 | 58 | 113 | 84 | |
| Inventory Days | 14 | 18 | 41 | 112 | 67 | |
| Days Payable | 88 | 123 | 106 | 248 | 80 | |
| Cash Conversion Cycle | -10 | -39 | -6 | -24 | 71 | |
| Working Capital Days | 2 | 1 | 15 | 46 | 83 | |
| ROCE % | 237% | 111% | 85% | 60% | 40% |
| Jun 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|
| Promoters | 73.53% | 73.53% | 73.53% |
| FIIs | 3.38% | 1.83% | 0.16% |
| DIIs | 10.46% | 6.83% | 5.65% |
| Public | 12.62% | 17.80% | 20.66% |
| No. of Shareholders | 2,403 | 1,022 | 1,335 |
Fundamentals
Market Cap₹ 609 Cr.
Current Price₹ 263
Stock P/E29.6
Book Value₹ 43.5
ROCE40.0 %
ROE30.0 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)40%
Compounded Profit Growth (TTM)54%
Standalone figures.
Valuation
Market capRs 593 Cr
Enterprise valueRs 592 Cr
P/E (TTM)131.70x
Price to book130.83x
Price to sales10.01x
EV / EBITDA94.84x
EV / EBIT96.70x
EV / sales10.00x
Price to cash flow138.15x
Earnings yield0.76%
Profitability
Operating margin (excl. other income)10.54%
Operating margin (incl. other income)10.54%
EBITDA margin10.54%
Pre-tax margin10.27%
Net profit margin7.60%
ROE99.34%
ROCE119.07%
ROA51.11%
ROIC (approx.)123.70%
Tax rate25.82%
Per share
EPS (TTM)Rs 1.94
EPS (latest year)Rs 1,800.00
Book value per shareRs 1.96
Sales per shareRs 25.57
Cash flow per shareRs 1.85
Free cash flow per shareRs -9.07
Efficiency
Asset turnover3.37x
Fixed asset turnover21.61x
Inventory turnover27.58x
Inventory days13 days
Debtor days64 days
Debtors turnover5.74x
Creditor days80 days
Cash conversion cycle71 days
Working capital days83 days
Leverage
Total debtRs 1 Cr
Cash and bankRs 1 Cr
Net debtRs -1 Cr
Debt to equity0.13x
Net debt / EBITDA-0.14x
Interest coverage153.00x
Owners' fund to total sources25.75%
Debt to assets3.47%
Cash flow
Cash from Operating Activity (latest year)Rs 4 Cr
Cash from Investing Activity (latest year)Rs -3 Cr
Cash from Financing Activity (latest year)Rs 1 Cr
Net Cash Flow (latest year)Rs 1 Cr
Free cash flow (latest year)Rs -21 Cr
Cash from ops / profit, 5 years0.55x
Sales to cash flow13.80x
Statement figures
Net sales (TTM)Rs 59 Cr
Net sales (latest year)Rs 59 Cr
Operating profit excl. other income (latest year)Rs 6 Cr
EBITDA (TTM)Rs 6 Cr
PBDT (TTM)Rs 6 Cr
Profit before tax (TTM)Rs 6 Cr
Tax (latest year)Rs 2 Cr
Net profit (TTM)Rs 4 Cr
Net profit (latest year)Rs 4 Cr
Depreciation (TTM)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 48 Cr
Total expenditure (latest year)Rs 53 Cr
Total income (latest year)Rs 59 Cr
Share capitalRs 0 Cr
ReservesRs 4 Cr
Shareholders' fundsRs 5 Cr
Total assetsRs 18 Cr
Net blockRs 3 Cr
ReceivablesRs 10 Cr
InventoryRs 2 Cr
Other liabilitiesRs 12 Cr
Shares outstanding (crore)2.31
Ownership
Promoter holding73.53%
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | INFLUX | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -8.7% | -2.8% | -6.0 pts |
| 1 month | -12.5% | -6.8% | -5.7 pts |
| 3 months | -15.0% | -7.6% | -7.4 pts |
| 6 months | +26.7% | +0.4% | +26.3 pts |
| 1 year | +45.6% | -9.9% | +55.5 pts |
Red flags
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
No quarterly results published.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Less than 100 unique PAN traded in previous 30 daysSME scrip is not regularly traded
Quick answers
What is the market cap of Influx Healthtech Ltd?
Influx Healthtech Ltd (INFLUX) has a market capitalisation of Rs 609 Cr. at the 2026-10-01 close.
What is the P/E ratio of Influx Healthtech Ltd?
Influx Healthtech Ltd trades at a P/E of 29.6 on trailing twelve-month profit, at the 2026-10-01 close.
What is the 52-week high and low of Influx Healthtech Ltd?
The 52-week high is Rs 315.00 and the 52-week low is Rs 160.60.